All In Biotech

Drug Trial Radar · NCT02606461

Selinexor in Advanced Liposarcoma

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Last checked: Nov 20, 2026Latest source record: Jan 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 342 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

342

Actual

Start

Jan 4, 2016

Primary completion

Oct 28, 2020

Study completion Oct 26, 2021

Sponsor

Lead sponsor
Karyopharm Therapeutics IncIndustry
Sponsor type
Industry
First posted
Nov 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).

Conditions

  • Dedifferentiated Liposarcoma

Interventions

  • SelinexorDrug

    Selinexor 60mg

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
  2. Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1Time frame: From the date of randomization in the Phase 3 open label period until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
  3. Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1Time frame: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
  4. Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1Time frame: From date of randomization in the Phase 2 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)

Locations

71 sites in 10 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California, Los Angeles

    Los Angeles, California

  • Sarcoma Oncology Center

    Santa Monica, California

  • Stanford University

    Stanford, California

  • University of Colorado-Denver

    Denver, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Mayo Clinic

    Jacksonville, Florida

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Johns Hopkins

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Northwell Health Physicians Partners

    New York, New York

  • Duke Institute of Cancer

    Durham, North Carolina

  • James Cancer Center, Ohio State University

    Columbus, Ohio

  • Oregon Health and Science

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, Pennsylvania

  • Vanderbilt

    Nashville, Tennessee

  • MD Anderson

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • UZ Brussel

    Brussels, Belgium

  • UCL Saint-Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • Cross Cancer Center - Alberta Health Services

    Edmonton, Alberta, Canada

  • The Ottawa Hospital Cancer

    Ottawa, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • McGill University

    Montreal, Quebec, Canada

  • Institut Bergonie

    Bordeaux, France

  • Oscar Lambret Center

    Lille, France

  • Centre Leon Berard

    Lyon, France

  • Timone University Hospital

    Marseille, France

  • Institut Régional du Cancer de Montpellier (ICM)

    Montpellier, France

  • CLCC Antoine Lacassagne

    Nice, France

  • Institut Curie

    Paris, France

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.